Literature DB >> 21805081

Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Fabio Silvio Taccone1, Maya Hites, Marjorie Beumier, Sabino Scolletta, Frédérique Jacobs.   

Abstract

Antibiotic treatment of critically ill patients remains a significant challenge. Optimal antibacterial strategy should achieve therapeutic drug concentration in the blood as well as the infected site. Achieving therapeutic drug concentrations is particularly difficult when infections are caused by some pathogens, such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative rods, because of their low susceptibility to antimicrobials. In sepsis, pharmacokinetics (PKs) of antibiotics are profoundly altered and may result in inadequate drug concentrations, even when recommended regimens are used, which potentially contribute to increased mortality and spread of resistance. The wide inter-individual PK variability observed in septic patients strongly limits the a priori prediction of the optimal dose that should be administered. Higher than standard dosages are necessary for the drugs, such as β-lactams, aminoglycosides, and glycopeptides, that are commonly used as first-line therapy in these patients to maximize their antibacterial activity. However, the benefit of reaching adequate drug concentrations on clinical outcome needs to be further determined.

Entities:  

Year:  2011        PMID: 21805081     DOI: 10.1007/s11908-011-0203-y

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  96 in total

Review 1.  Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care.

Authors:  N Petrosillo; C M Drapeau; M Agrafiotis; M E Falagas
Journal:  Minerva Anestesiol       Date:  2010-07       Impact factor: 3.051

2.  Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients.

Authors:  Kazuro Ikawa; Norifumi Morikawa; Seiichi Hayato; Kayo Ikeda; Hiroki Ohge; Taijiro Sueda
Journal:  Int J Antimicrob Agents       Date:  2007-06-22       Impact factor: 5.283

3.  First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.

Authors:  Jason A Roberts; Carl M J Kirkpatrick; Michael S Roberts; Andrew J Dalley; Jeffrey Lipman
Journal:  Int J Antimicrob Agents       Date:  2009-12-16       Impact factor: 5.283

4.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

5.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

6.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions.

Authors:  A J Larsson; K J Walker; J K Raddatz; J C Rotschafer
Journal:  J Antimicrob Chemother       Date:  1996-10       Impact factor: 5.790

8.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

9.  Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Vikas P Chaubey; Johann Dd Pitout; Bruce Dalton; Terry Ross; Deirdre L Church; Daniel B Gregson; Kevin B Laupland
Journal:  BMC Res Notes       Date:  2010-04-27

10.  Pharmacokinetic dosing of aminoglycosides: a controlled trial.

Authors:  Carmi Bartal; Abraham Danon; Francisc Schlaeffer; Klaris Reisenberg; Michael Alkan; Rosa Smoliakov; Aviel Sidi; Yaniv Almog
Journal:  Am J Med       Date:  2003-02-15       Impact factor: 4.965

View more
  9 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

2.  Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Authors:  Sutep Jaruratanasirikul; Suriyan Thengyai; Wibul Wongpoowarak; Thitima Wattanavijitkul; Kanyawisa Tangkitwanitjaroen; Waroonrat Sukarnjanaset; Monchana Jullangkoon; Maseetoh Samaeng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.

Authors:  Muhammad Usman; Otto R Frey; Georg Hempel
Journal:  Eur J Clin Pharmacol       Date:  2016-12-13       Impact factor: 2.953

4.  Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.

Authors:  Sutep Jaruratanasirikul; Wibul Wongpoowarak; Thitima Wattanavijitkul; Waroonrat Sukarnjanaset; Maseetoh Samaeng; Monchana Nawakitrangsan; Natnicha Ingviya
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams.

Authors:  Nicolas Dufour; Raphaëlle Delattre; Jean-Damien Ricard; Laurent Debarbieux
Journal:  Clin Infect Dis       Date:  2017-06-01       Impact factor: 9.079

6.  A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.

Authors:  Anders Thorsted; Salim Bouchene; Eva Tano; Markus Castegren; Miklós Lipcsey; Jan Sjölin; Mats O Karlsson; Lena E Friberg; Elisabet I Nielsen
Journal:  PLoS One       Date:  2019-02-21       Impact factor: 3.240

7.  Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.

Authors:  Jörn Grensemann; David Busse; Christina König; Kevin Roedl; Walter Jäger; Dominik Jarczak; Stefanie Iwersen-Bergmann; Carolin Manthey; Stefan Kluge; Charlotte Kloft; Valentin Fuhrmann
Journal:  Ann Intensive Care       Date:  2020-04-22       Impact factor: 6.925

8.  Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.

Authors:  Sutep Jaruratanasirikul; Veerapong Vattanavanit; Wibul Wongpoowarak; Monchana Nawakitrangsan; Maseetoh Samaeng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.441

Review 9.  Ultrasound-mediated therapies for the treatment of biofilms in chronic wounds: a review of present knowledge.

Authors:  Gareth LuTheryn; Peter Glynne-Jones; Jeremy S Webb; Dario Carugo
Journal:  Microb Biotechnol       Date:  2019-08-07       Impact factor: 5.813

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.